Soligenix CEO to Present at H.C. Wainwright Global Investment Conference
TL;DR
Soligenix CEO's presentation at H.C. Wainwright conference offers investors early insight into potential regulatory approvals and commercialization opportunities for rare disease treatments.
Soligenix will present at the H.C. Wainwright conference on September 5-10, 2025, with on-demand access and one-on-one meetings available through the platform.
Soligenix's rare disease treatments and vaccines address unmet medical needs, potentially improving lives worldwide through innovative biopharmaceutical solutions.
Soligenix develops novel photodynamic therapy for cutaneous T-cell lymphoma and heat-stabilized vaccines using proprietary ThermoVax technology for global health threats.
Found this article helpful?
Share it with your network and spread the knowledge!
Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company, announced that President and CEO Christopher J. Schaber, Ph.D., will deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8–10, 2025. The on-demand presentation will be accessible starting September 5 at 7 a.m. ET through the conference platform, with Soligenix management also engaging in one-on-one meetings during the event.
The company's Specialized BioTherapeutics business segment is advancing HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy using safe visible light for treating cutaneous T-cell lymphoma (CTCL). Following the successful completion of a second Phase 3 study, Soligenix plans to seek regulatory approvals to support potential global commercialization. Additional development programs include expanding synthetic hypericin (SGX302) into psoriasis treatment, and advancing first-in-class innate defense regulator technology with dusquetide (SGX942) for inflammatory diseases such as oral mucositis in head and neck cancer, and SGX945 for Behçet’s Disease.
Soligenix's Public Health Solutions business segment focuses on vaccine candidates, including RiVax® for ricin toxin, filovirus vaccines targeting Marburg and Ebola, and CiVax™ for COVID-19 prevention. These programs utilize the proprietary heat stabilization platform technology ThermoVax®. This segment has been supported by government grant and contract funding from entities such as the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).
The presentation at the H.C. Wainwright conference underscores Soligenix's commitment to addressing rare diseases with significant unmet medical needs, potentially impacting patient care and public health. Investors and stakeholders can access further updates through the company's newsroom at https://ibn.fm/SNGX. The event provides a platform for Soligenix to highlight its progress and future strategies, which could influence investment decisions and industry collaborations.
Curated from InvestorBrandNetwork (IBN)
